Addressing Emotional Distress in Dyads of Persons With a Young Onset Dementia (YOD) and Their Care-partners
Launched by MASSACHUSETTS GENERAL HOSPITAL · Jun 4, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help people who have Young Onset Dementia (YOD) and their care-partners manage emotional distress. The study will test a virtual program that includes six sessions for both the person with dementia and their caregiver. The goal is to help both individuals feel better emotionally, build resilience, and improve their overall quality of life.
To participate in this study, both the person with YOD and their care-partner need to be between the ages of 18 and 65 and must have a recent diagnosis of dementia. They should also be able to understand and communicate in English and have some level of emotional distress. However, those with other serious health issues or certain mental health conditions may not be eligible. Participants can expect to engage in helpful sessions that aim to strengthen their emotional well-being together, all from the comfort of their own home.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between the ages of 18-65 at the time of enrollment \[both patient and care-partner\]
- • Diagnosis of young-onset dementia (FTD, PPA, AD, PCA, etc.) with symptom onset prior to age 65 \[patient\]
- • A designated care-partner willing and interested to participate \[both patient and care-partner\]
- • Received YOD diagnosis in the past 6 month \[patient\]
- • English fluency and literacy \[both patient and care-partner\]
- • Cognitive ability to understand study and research protocol in order to consent to study participation \[both patient and care-partner\]
- • Patient and/or caregiver exhibit emotional distress on screening (using HADS D and/or HADS A scores \> 7)
- Exclusion Criteria:
- • And additional, terminal diagnosis such as cancer
- • Lack of access to internet and/or a device with a camera
- • Current untreated or unstable severe mental health conditions like bipolar disorder, schizophrenia, or active substance use
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported